BTQ Technologies Corp. - Common Stock (BTQ)

Aprea Therapeutics (Nasdaq: APRE) a clinical-stage oncology company developing next-generation cancer therapies — reported strong third-quarter progress as its lead drug programs continue to show encouraging clinical activity in multiple genetically driven cancers. The company’s precision-oncology approach targets defects in DNA damage repair (DDR) pathways including p53, WEE1, and ATR, which are common drivers of aggressive solid tumors and blood cancers such as colorectal, endometrial, ovarian, pancreatic, lung cancers, MDS, and AML .